
Lucid Diagnostics Inc.: updates and filings
Price
$0.37
November 20, 2026Market cap $77M
What Ploutos Investor adds for Lucid Diagnostics
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 22, 2026Unregistered sale of shares, change to shareholders' rights, amended articles or bylawsForm8-K
- Oct 16, 2026Delisting noticeForm8-K
- Sep 22, 2026Regulation FD disclosureForm8-K
- Aug 13, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jun 24, 2026Amended articles or bylaws, shareholder voteForm8-K
- May 14, 2026Results of operations, Regulation FD disclosureForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 24, 2026Regulation FD disclosure, other material eventsForm8-K
- Apr 23, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Apr 20, 2026Preliminary proxy statementFormPRE 14A
- Apr 3, 2026Shares registered for employeesFormS-8
- Apr 3, 2026Shares registered for employeesFormS-8
- Mar 26, 2026FilingFormEFFECT
- Mar 26, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 26, 2026Shelf registration for future offerings (amendment)FormS-3/A
- Mar 25, 2026Correspondence with the SECFormCORRESP
- Mar 25, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 9, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Dec 5, 2025Shelf registration for future offeringsFormS-3
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 22, 2026 | 8-K | Unregistered sale of shares, change to shareholders' rights, amended articles or bylaws | Document |
| Oct 16, 2026 | 8-K | Delisting notice | Document |
| Sep 22, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 13, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jun 24, 2026 | 8-K | Amended articles or bylaws, shareholder vote | Document |
| May 14, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 24, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Apr 23, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Apr 20, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Apr 3, 2026 | S-8 | Shares registered for employees | Document |
| Apr 3, 2026 | S-8 | Shares registered for employees | Document |
| Mar 26, 2026 | EFFECT | Filing | Document |
| Mar 26, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 26, 2026 | S-3/A | Shelf registration for future offerings (amendment) | Document |
| Mar 25, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 25, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 9, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Dec 5, 2025 | S-3 | Shelf registration for future offerings | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 21, 2020.
The full analysis
What do Lucid Diagnostics's filings show?
The filings are where every one of Lucid Diagnostics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.